Drugs moving into the clinic: 1

- Last updated on GMT

The first in a new series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Sponsor Name Indication Mechanism
Enzon Pharmaceuticals & Santaris SPC2968 Oncology Hypoxia Inducible Factor 1 alpha (HIF-1 alpha) antagonist - tagetting angiogenesis, cell proliferation, apoptosis, cell invasion
Celsus Laboratorie Intimatan Anti- coagulent: For example, to prevent blood clots during cardiac surgery (replacing heparin) heparin cofactor II agonist
CoGenesys Neugranin decrease infection in patients receiving myelo- suppressive anti-cancer drugs long-acting form of Granulocyte Colony Stimulating Factor (G-CSF)
BN Immuno- Therapeutics MVA-BN(R)-HER2 Oncology - breast cancer vaccine Induce multi-pronged immunity as well as anti-tumor activity
Medivir MV-701 osteoporosis, osteoarthritis, rheumatoid arthritis, Paget's disease and certain tumours causing bone metastases Cathepsin K inhibitor

Related topics: Preclinical Research

Related news

Show more